Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juhua Shuxin Pian is a Traditional Chinese Medicine (TCM) product developed by the Zhejiang Modern Chinese Medicine and Natural Medicine Research Institute. It is primarily indicated for the treatment of coronary heart disease (CHD) and stable angina pectoris. The formulation is derived from the extract of Chrysanthemum (*Chrysanthemum morifolium*), which is rich in bioactive flavonoids and phenolic acids. These components are reported to exert cardioprotective effects by promoting vasodilation of the coronary arteries, increasing coronary blood flow, and reducing myocardial oxygen consumption. Additionally, the drug exhibits antioxidant properties that help mitigate oxidative stress in vascular tissues, thereby improving clinical symptoms such as chest pain and palpitations in patients with myocardial ischemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on juhua shuxin pian.